علاج التذكير عند وجود موانع للعلاجات المحتوية على الإستروجين

References

Medroxyprogesterone acetate has been recommended for use in patients with contraindications to estrogen-containing therapies (i.e., CHCs).

Although short courses of oral medroxyprogesterone acetate (to induce a withdrawal bleed in individuals with PCOS) have been shown to reduce androgen levels, there are no studies assessing efficacy of long-term therapy.

DOI: 10.1016/j.jogc.2023.102272